Is CJC-1295 No DAC from Lumera Labs HPLC verified?

Yes. Every CJC-1295 No DAC lot Lumera Labs ships is HPLC-purity tested at synthesis and retested by Janoshik Analytical before release. The lot-specific Certificate of Analysis is published on the Lab Results page.

Is CJC-1295 No DAC sold for human use?

No. CJC-1295 No DAC is sold strictly as a laboratory reference standard for in-vitro research. It is not approved by Health Canada or the FDA for human use. Every order requires a research-use declaration.

How is CJC-1295 No DAC shipped?

CJC-1295 No DAC is lyophilized at synthesis, sealed under nitrogen, and shipped from Kelowna, BC at -20 C through cold-chain insulated packaging via Canada Post Xpresspost. Free shipping over $200 CAD. 24-48h transit Canada-wide.

Where can I see the COA for CJC-1295 No DAC?

Each shipment includes a lot-specific Certificate of Analysis. The current lot's COA is also published at https://lumerapeptide.com/lab-results/ and can be cross-referenced by the batch number printed on each vial.

4.7 · 220 researcher reviews

Growth axis · GHRH analog

CJC-1295 No DAC

SKU LUM-CJC1295-5 · C₁₅₂H₂₅₂N₄₄O₄₂ · 3367.93 g/mol · CAS 863288-34-0

A short-acting growth-hormone-releasing-hormone analog without the drug-affinity complex. Studied for pulsatile GH release in research models.

Purity (HPLC): ≥ 99.34%
Net peptide: 5.00 mg ± 2%
Endotoxin: < 0.5 EU/mg
Format: Lyophilized vial
Storage: −20 °C, desiccated
Shelf life: 24 months from MFG

$90CAD / 10 mg vial

In stock · Lot 26-A031

Bulk 10+: $24 / vial

Add $200 for free cold-chain shipping

HPLC + MS verified per lot
Cold-chain to your door
COA bundled with shipment
Lot retains kept 5 years

Overview

CJC-1295 (no DAC) is a synthetic 30-residue analog of GHRH(1-29) with four amino acid substitutions (D-Ala²/Gln⁸/Ala¹⁵/Leu²⁷) that enhance plasma stability and GHRH-receptor potency. Without the drug-affinity complex (DAC) modification, the peptide retains the natural pulsatile pharmacokinetics of GHRH agonism.

Each vial is lyophilized from acetate buffer, sealed under nitrogen, and shipped cold-chain at −20 °C from our Kelowna facility.

Research applications

GHRH-receptor binding assays, in-vitro pituitary GH-secretion screens, and comparative pharmacokinetics versus DAC-modified analogs and natural GHRH(1-29).

Sold for laboratory research only. This material is not a drug, food, or cosmetic and is not intended for diagnostic, therapeutic, or recreational use.

Identity

Parameter	Value
Sequence	Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH₂
Molecular formula	C₁₅₂H₂₅₂N₄₄O₄₂
Molecular weight	3367.93 g/mol
CAS number	863288-34-0
Length	30 residues

Quality

Test	Specification
HPLC purity	≥ 99.0% (lot LM-2615: 99.21%)
Mass confirmation	ESI-MS within 0.5 Da
Net peptide content	≥ 80% by AAA
Endotoxin	< 0.5 EU/mg (LAL)
Bioburden	< 10 CFU/g
Residual TFA	< 1.0%

Lot LM-2615

Manufactured 04 Mar 2026 · Released 11 Mar 2026 · Tested by Lumera QC, Kelowna BC. Retain samples held under storage spec for five years from release date.

Verification

Method	Result
RP-HPLC at 220 nm	99.21% main peak
ESI-MS (positive)	3367.9 Da (theor. 3367.93)
Amino acid analysis	82.1% net peptide
LAL endotoxin	< 0.05 EU/mg
Karl Fischer (water)	2.8% w/w

Reconstitution

Allow vial to reach room temperature before opening (≥ 20 minutes). Reconstitute with 1.0–2.5 mL of sterile bacteriostatic water (0.9% benzyl alcohol). Inject solvent slowly down the inner wall of the vial; do not direct stream onto the lyophilized cake.

Swirl gently for 30 seconds. Do not vortex. Allow to dissolve for 5 minutes; clarity should be complete with no visible particulates.

Storage after reconstitution

Reconstituted solution is stable for 28 days at 2–8 °C in original vial. For longer storage, aliquot into low-binding tubes and hold at −80 °C; avoid repeated freeze-thaw cycles. Discard if turbidity, color change, or particulate matter is observed.

Selected references

Teichman SL et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295. J Clin Endocrinol Metab. 2006;91(3):799–805.

Sackmann-Sala L, Kopchick JJ. Growth hormone receptor signaling and disease. Mol Cell Endocrinol. 2014;392(1-2):1–8.

Veldhuis JD, Bowers CY. Integrating GHRH agonism and ghrelin-receptor agonism. Endocrine. 2010;38(1):1–16.

Citing this material

CJC-1295 No DAC reference standard, ≥99% (HPLC), Lumera Labs Inc., Cat. No. LUM-CJC1295-5, Lot 26-A031.

Related · Growth axis

Often paired in studies.

View catalog →

GLP-1/GIP · Metabolic

Tirzepatide

10 mg · ≥ 99.3%

$40 CADView →

Tri-agonist · Metabolic

Retatrutide

10 mg · ≥ 99.2%

$85 CADView →

Metabolic

Cagrisema

10 mg · ≥ 99.1%

$72 CADView →

Growth axis

AOD-9604

10 mg · ≥ 99.0%

$36 CADView →

Why Lumera

Janoshik Analytical HPLC ≥ 99.34% on this lot
LC-MS identity confirmed before release
LAL endotoxin below detection limit
Cold-chain shipped −20°C from Kelowna, BC

Background research

What the literature says about Cjc 1295.

Mechanism

Cjc 1295 is a GHRH analog, classified within the growth-axis signaling pathway. Structurally it is a 30-residue D-Ala-modified GHRH. CJC-1295 (no DAC) is a synthetic 30-residue analog of growth-hormone-releasing hormone (GHRH 1-29) with substitutions at positions 2, 8, 15, and 27 conferring DPP-IV resistance and extended half-life. Teichman et al. (2006) characterized its pharmacokinetics.

In an in-vitro setting, Cjc 1295 interacts with its target receptor(s) at low-nanomolar affinities under standard binding-assay conditions. Reconstitution should be performed in sterile bacteriostatic water at the working concentration your protocol specifies; the lyophilized vial is sealed under nitrogen and stable at −20 °C until reconstituted.

Common research applications

In-vitro receptor-binding and dose-response screens against the growth-axis signaling target panel.
Comparative pharmacology against related class members and previously published reference standards.
Time-course studies leveraging Cjc 1295's known stability profile.
Cross-batch HPLC fingerprint comparison against the lot-specific COA we publish for every release.

Storage & handling

Cjc 1295 arrives lyophilized at −20 °C in cold-chain insulated packaging. On receipt, transfer immediately to a −20 °C freezer. Once reconstituted, store at 2-8 °C and use within the window noted on the lot's COA. Avoid repeated freeze-thaw cycles.

References

Teichman SL et al. J Clin Endocrinol Metab. 2006;91(3):799-805.
Sigalos JT, Pastuszak AW. Sex Med Rev. 2018;6(1):86-90.
Ionescu M, Frohman LA. J Clin Endocrinol Metab. 2006;91(12):4792-7.

For laboratory research only. Cjc 1295 is sold strictly as an in-vitro reference standard. It is not approved for human or veterinary use by Health Canada or the FDA.